Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cangpo Liujun Prescription on Cancer-related Fatigue in Advanced Colorectal Cancer With Spleen Deficiency and Dampness Excess
Sponsor: First People's Hospital of Hangzhou
Summary
The goal of this clinical trial is to learn if Cangpo Liujun Prescription works to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy with spleen deficiency and dampness excess. It will also learn about the safety of Cangpo Liujun Prescription. The main questions it aims to answer are: Does Cangpo Liujun Prescription improve the fatigue symptoms for participants? How about the relationship between taking Cangpo Liujun Prescription and distribution of intestinal flora? Researchers will compare Cangpo Liujun Prescription to a placebo (a look-alike substance that contains no drug) to see if Cangpo Liujun decoction works to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy with spleen deficiency and dampness excess. Participants will: Take Cangpo Liujun Prescription or a placebo every day for 3 months Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms Take blood samples to detect immune function and inflammatory factors Collected Feces for gut microbiota analysis
Official title: Study on the Curative Effect of Cangpo Liujun Prescription on Cancer-related Fatigue in Patients With Advanced Colorectal Cancer Undergoing Second-line Chemotherapy With Spleen Deficiency and Dampness Excess and Analysis of Intestinal Flora
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2024-04-30
Completion Date
2026-04-01
Last Updated
2024-05-01
Healthy Volunteers
No
Conditions
Interventions
Cangpo Liujun Prescription
Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
Locations (1)
Hangzhou First People' Hospital
Hangzhou, Zhejiang, China